Discovery of potent substrate-type lysine methyltransferase G9a inhibitors for the treatment of sickle cell disease
- 11 May 2025
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 293, 117721
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development
- RIKEN
- Japan Society for the Promotion of Science (23H05473)
This publication has 50 references indexed in Scilit:
- Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatmentBioorganic & Medicinal Chemistry Letters, 2024
- Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndromeMolecular Therapy, 2024
- Lysine long-chain fatty acylation regulates the TEAD transcription factorCell Reports, 2023
- Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidinesBioorganic & Medicinal Chemistry Letters, 2020
- Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agentsEuropean Journal of Medicinal Chemistry, 2019
- Towards good correlation between fragment molecular orbital interaction energies and experimental IC 50 for ligand binding: A case study of p38 MAP kinaseComputational and Structural Biotechnology Journal, 2018
- Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological ImpactMolecular Cell, 2012
- Development of the four-body corrected fragment molecular orbital (FMO4) methodChemical Physics Letters, 2012
- Chemical mechanisms of histone lysine and arginine modificationsBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2009
- Structure‐Based Design, Synthesis, and in vitro Evaluation of Nonpeptidic Neprilysin InhibitorsChemBioChem, 2004